Myasthenia gravis market to reach $13.0bn across 7MM by 2034 - Pharmaceutical Technology

The myasthenia gravis (MG) market across the 7MM is poised to grow at a CAGR of 11.1% from $4.5bn in 2024 to $13.0bn in 2034. MG treatment regimens are determined through the classification of a patient’s clinical status and autoantibody status. The management of refractory myasthenia gravis involves more aggressive and targeted therapies than those used in non-refractory cases. Credit: Jack_the_sparow via Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you can: The leading site for…

Source: Pharmaceutical Technology